Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- AIN PHARMACIEZ Issues Membership Cards
April 2, 2001
- 18.6% of Inpatients Can Be Discharged: Survey
April 2, 2001
- Sales of OTC Drugs in FY2000 Likely to Drop Due to Poor Prevalence of Flu
April 2, 2001
- Percentage of Deficit-ridden Hospitals Declines Slightly: NHFJ Survey
April 2, 2001
- Functional health food system to start april
April 2, 2001
- REGULATORY NEWS IN BRIEF
April 2, 2001
- COX-2 Inhibitors Show Effects against Cancer
April 2, 2001
- Korosho Urges Generic Makers to Ensure Stable Supply of Their Products
April 2, 2001
- Hp Eradication Saves 320 Bil. in Medical Expenses in 5 Years: Takeda Seminar
April 2, 2001
- BULLETIN
April 2, 2001
- Osteo Genesis Starts Developing Bone Regeneration Technology
April 2, 2001
- BUSINESS NEWS IN BRIEF
April 2, 2001
- MediBIC Licenses Haplotyping Technology from Genaissance
April 2, 2001
- Toho Transfers Business to Affiliated Companies to Increase Efficiency
April 2, 2001
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…